Lexeo Therapeutics to Host Investor Event on Clinical Endpoints in PKP2-ACM
Bitget2026/10/19 11:14- Lexeo Therapeutics will host an educational investor event on PKP2 arrhythmogenic cardiomyopathy on Oct. 21, 2026, at 1 p.m. ET.
- The discussion will focus on clinical assessments of arrhythmias used to evaluate disease burden and treatment response.
- Speakers include Chief Medical Officer Narinder Bhalla and Cleveland Clinic physician-scientist Alessio Gasperetti.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Palantir (PLTR.US) partners with cloud custody service provider Knox to accelerate cloud deployment of critical software for the U.S. government
Palantir announced a new agreement with cloud custody service provider Knox Systems on Monday to deliver software services to the U.S. federal government via the cloud.
JPMorgan: Stabilization of bond yields may end valuation compression, combined with accelerating earnings, stock market expected to rise through the end of the year
JPMorgan stated that stabilized yields may help extend the stock market rally through the end of the year.
Nasdaq Stocks Could Crash 30% If This Happens, Experts Warn
Wells Fargo: This earnings season marks "one of the weakest starts for EPS in history," with most companies underperforming expectations
Wells Fargo stated that the start of this US earnings season has been unfavorable. In its report, the bank wrote that only about a week into the third-quarter earnings season, the earnings per share of companies that have reported results are already 0.3% lower than analysts’ general expectations.
Crypto prices
More
